Precision Therapeutics for Women's Health
Treating chronic women's health diseases at the source.
Esma Bio is a biotechnology company developing precision genetic medicines for chronic women's health diseases. Our lead program is an RNA-based therapeutic that acts within endometriotic lesions to silence the disease at its source — without the systemic hormonal suppression, bone loss, or duration limits of current care.
190M
affected by endometriosis
7–10 yrs
average diagnostic delay
Recurrence
after treatment is common
The Unmet Need
Endometriosis has been stuck in a hormonal paradigm for decades.
Affecting nearly 190 million women globally, endometriosis remains one of the most underserved diseases in modern medicine — still managed with hormonal suppression and surgery, approaches that manage symptoms without addressing underlying disease biology.
190M
women affected globally
7–10 yrs
average diagnostic delay
Recurrence
after treatment is common
Disease Burden
A debilitating disease, often invisible
Endometriosis causes chronic pelvic pain, infertility, and systemic inflammation. Patients endure years of misdiagnosis before reaching a specialist, and many lose career years and quality of life to a disease that is still poorly understood and undertreated.
Treatment Limitations
Hormones and surgery — neither is a cure
Existing therapies suppress estrogen system-wide, carrying bone-density and tolerability penalties that limit their duration of use. Surgery is invasive and the disease frequently recurs. No therapy on the market addresses the underlying biology of the lesion itself.
The Esma Bio Approach
Beyond hormones and surgery.
Esma Bio is developing an RNA-based, lesion-selective therapeutic designed to act locally within endometriotic lesions while sparing normal systemic endocrine function — an alternative to the system-wide hormonal suppression and surgery that define current care.
Development Roadmap
From candidates to clinic.
Our pipeline spans two programs — a lead endometriosis candidate (ESB-001) and an earlier-stage oncology program (ESB-002) — advancing through the studies needed to support future clinical filings.
Detailed timelines and regulatory strategy are shared with qualified partners under CDA.